Edge Rewrite
pun Source code View original
Jump to content

// Workers AI · dad joke modeWhat did UCD0830 say to its date? "You're a byte above the rest.

Add links
From Wikipedia, the free encyclopedia

UCD0830
Clinical data
Other namesUCD-0830; N,N-Dimethyl-2-aminotetralin; N,N-DiMe-2-AT
Drug classSerotonin 5-HT2C receptor agonist
ATC code
  • None
Identifiers
  • N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N
Molar mass175.275 g·mol−1
3D model (JSmol)
  • CN(C)C1CCC2=CC=CC=C2C1
  • InChI=1S/C12H17N/c1-13(2)12-8-7-10-5-3-4-6-11(10)9-12/h3-6,12H,7-9H2,1-2H3
  • Key:WGCDXGZYCIMFTN-UHFFFAOYSA-N

UCD0830, also known as N,N-dimethyl-2-aminotetralin (N,N-DiMe-2-AT), is a serotonin receptor modulator of the 2-aminotetralin family.[1][2][3] It is the N,N-dimethyl derivative of 2-aminotetralin (2-AT) and is a cyclized phenethylamine as well as a partial ergoline.[1][2][3]

Pharmacology

[edit]

UCD0830 is a potent partial agonist of the serotonin 5-HT2C receptor, with an EC50Tooltip half-maximal effective concentration of 167 nM and an EmaxTooltip maximal efficacy of 52%.[1] It is selective for activation of this receptor over the serotonin 5-HT2A and 5-HT2B receptors, where it shows no significant agonism at concentrations of up to 10,000 nM.[1] However, UCD0830 shows weak but detectable affinity for the serotonin 5-HT2A receptor (Ki = 2,290 nM).[1] In accordance with its lack of serotonin 5-HT2A receptor agonism, UCD0830 did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[1] Other behavioral effects in animals have also been described.[3]

Chemistry

[edit]

The chemical synthesis of UCD0830 has been described.[1]

History

[edit]

UCD0830 was first described in the scientific literature by 1980.[2][3] Subsequently, it was studied and described in greater detail by David E. Olson and colleagues at the University of California, Davis in 2026.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 Basargin AG, Domokosa A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, et al. (September 2026). "Deconstruction of lysergic acid diethylamide". Proceedings of the National Academy of Sciences of the United States of America. 123 (38) e2603412123. doi:10.1073/pnas.2603412123. PMID 42709856.
  2. 1 2 3 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  3. 1 2 3 4 Cannon JG, Perez JA, Pease JP, Long JP, Flynn JR, Rusterholz DB, et al. (July 1980). "Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene". Journal of Medicinal Chemistry. 23 (7): 745–749. doi:10.1021/jm00181a009. PMID 7190613.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=UCD0830&oldid=1375952186"